Journal of Acquired Immune Deficiency Syndromes : Jaids
Overview
The Journal of Acquired Immune Deficiency Syndromes (JAIDS) is a leading scientific journal dedicated to publishing cutting-edge research on HIV/AIDS and related conditions. It covers a wide range of topics including epidemiology, prevention, treatment, and social aspects of the disease. With a focus on evidence-based medicine, JAIDS serves as a vital resource for healthcare professionals, researchers, and policymakers in the fight against HIV/AIDS.
Details
Details
Abbr.
J Acquir Immune Defic Syndr
Start
1999
End
Continuing
Frequency
Fifteen no. a year
p-ISSN
1525-4135
e-ISSN
1944-7884
Country
United States
Language
English
Specialty
Infectious Diseases
Metrics
Metrics
h-index / Ranks: 1068
171
SJR / Ranks: 2744
1225
CiteScore / Ranks: 4133
5.70
JIF / Ranks: 2654
3.6
Recent Articles
1.
Gutierrez Jr J, Montgomery E, Dilworth S, McNulty M, Colasanti J, Johnson M, et al.
J Acquir Immune Defic Syndr
. 2025 Mar;
PMID: 40079720
Background: Long-acting injectable cabotegravir and rilpivirine (CAB/RPV-LA) may overcome adherence barriers and provide treatment choice among people with HIV (PWH). However, little is known about the factors most likely to...
2.
Jones J, Siegler A, Glick J, Lucas I, Sullivan P, Sarkar S, et al.
J Acquir Immune Defic Syndr
. 2025 Mar;
98(5):429-433.
PMID: 40067782
Introduction: There are persistent race- and ethnicity-based disparities in HIV incidence among gay and bisexual men who have sex with men (GBMSM) in the United States, partially driven by inequities...
3.
Njuguna I, Moraa H, Mbwayo A, Nyapara F, Aballa C, Mugo C, et al.
J Acquir Immune Defic Syndr
. 2025 Mar;
PMID: 40064634
Background: Optimized treatment regimens have improved the survival of children/youth living with HIV (YLH) allowing them to pursue career goals. More YLH are now spending time in schools, but evidence...
4.
Siribelli A, Diotallevi S, Galli L, Muccini C, Morsica G, Lolatto R, et al.
J Acquir Immune Defic Syndr
. 2025 Mar;
98(5):e16.
PMID: 40063827
No abstract available.
5.
Dasgupta S, Tie Y, Buchacz K, Koenig L, Lu J, Beer L
J Acquir Immune Defic Syndr
. 2025 Mar;
PMID: 40047561
Background: The U.S.'s National HIV/AIDS Strategy (NHAS) prioritizes improving QoL among people with HIV (PWH) but co-occurrence of different aspects of QoL is not well described. We developed and applied...
6.
Chaillon A, Gaitan N, Taylor L, Wu K, Wansom T, Gianella S, et al.
J Acquir Immune Defic Syndr
. 2025 Mar;
PMID: 40045466
Background: Persons living with HIV (PWH) remain at risk for hepatitis C virus (HCV) acquisition despite antiretroviral therapy, particularly among those who inject drugs or engage in high-risk sexual behaviors....
7.
Philpott D, Curran K, Russell O, McClung R, Hallmark C, Pieczykolan L, et al.
J Acquir Immune Defic Syndr
. 2025 Mar;
PMID: 40045461
Background: Clusters of rapid HIV transmission indicate larger underlying networks that are not effectively reached by HIV prevention, testing, and care services. Starting in 2018, the Centers for Disease Control...
8.
Zhao Y, Holtman M, Mudaly V, van Zyl G, Maartens G, Meintjes G
J Acquir Immune Defic Syndr
. 2025 Mar;
PMID: 40029237
Background: Dolutegravir resistance has been reported more frequently in patients with prior treatment experience compared to those on dolutegravir in first-line antiretroviral therapy (ART). The widespread use of dolutegravir in...
9.
Mbengeranwa T, Ziemba L, Brummel S, Johnston B, Cassim H, Theron G, et al.
J Acquir Immune Defic Syndr
. 2025 Feb;
PMID: 40001275
Background: The impact on infant bone, growth, and renal health of in utero and breastmilk exposure to contemporary antiretroviral treatment (ART) remains unclear. Methods: 643 pregnant women with HIV in...
10.
Sconza R, Fernandes G, Bailey H, Peters H, Prieto Tato L, Ramos M, et al.
J Acquir Immune Defic Syndr
. 2025 Feb;
PMID: 39994844
Background: Raltegravir is an HIV integrase strand transfer inhibitor recommended for use in pregnancy. The aim of this study was to assess risk of birth defects and other suboptimal outcomes...